Gabriela Franco Marques

Gabriela Franco Marques

Auto-generated profile, based on publicly available information

Gabriela Franco Marques

Department of Dermatology, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Autoimmunity Reviews
Verified
Journal Article
Closed access
PCPaulo Criado
Paulo Criado
GMGabriela Franco Marques
Gabriela Franco Marques
TMThamara Cristiane Alves Batista Morita
Thamara Cristiane Alves Batista Morita
JCJozélio Freire de Carvalho
Jozélio Freire de Carvalho

26 March 2020 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
TMThâmara Cristiane Alves Batista Morita
Thâmara Cristiane Alves Batista Morita
GTGabriela Franco S. Trés
Gabriela Franco S. Trés
RCRoberta Fachini Jardim Criado
Roberta Fachini Jardim Criado
MSMirian Sotto
Mirian Sotto
PCPaulo Criado
Paulo Criado
The term vasculitis refers to the inflammation of vessel walls. It may range in severity from a self-limited disorder in one single organ to a life-threatening disease due to multiple organ failure. It has many causes, although they result in only a few histological patterns of vascular inflammation. Vessels of any type and in any organ can be affected, a fact that results in a broad variety of signs and symptoms. Different vasculitides with indistinguishable clinical presentations have quite different prognosis and treatments. This condition presents many challenges to physicians in terms of classification, diagnosis, appropriate laboratory workup, and treatment. Moreover, it compels a careful follow-up. This article reviews the Chapel-Hill 2012 classification, etiology, recent insights in pathophysiology, some important dermatological clues for the diagnosis and summarizes treatment of some of these complex vasculitis syndromes.

25 July 2020 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
PCPaulo Criado
Paulo Criado
CPCarla Pagliari
Carla Pagliari
RCRoberta Fachini Jardim Criado
Roberta Fachini Jardim Criado
GMGabriela Franco Marques
Gabriela Franco Marques
WJWalter Belda Jr
Walter Belda Jr
COVID‐19 pandemic presents several dermatological manifestations described in the present indexed literature, with around 700 cases reported until May 2020, some described as urticaria or urticarial rashes. Urticaria is constituted by evanescent erythematous‐edematous lesions (wheals and flare), which does not persist in the same site for more than 24‐48 hours and appears in other topographic localization, resolving without residual hyper pigmentation. During the SARS‐CoV‐2 infection, some cytokines are synthesized, including Interferon type I, TNF‐α, and chemokines which may induce mast cells and basophils degranulation by mechanisms similar to the autoinflammatory monogenic or polygenic diseases. In this article we discuss the spectrum of the urticaria and urticarial‐like lesions in the COVID‐19's era, besides other aspects related to innate and adaptative immune response to viral infections, interactions between dermal dendritic cells and mast cells, degranulation of mast cells by different stimuli. Plasmacytoid dendritic cells share in allergic patients expression of the high affinity IgE receptors on cell membranes and demonstrated a low pattern of type I interferon secretion in viral infections. We discuss the previous descriptions of the effects of omalizumab, a monoclonal antibody directed to IgE and high affinity IgE receptors, to improve the interferon responses and enhance their antiviral effects.

1 July 2020 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
TMThâmara Cristiane Alves Batista Morita
Thâmara Cristiane Alves Batista Morita
PCPaulo Criado
Paulo Criado
RCRoberta Fachini Jardim Criado
Roberta Fachini Jardim Criado
GTGabriela Franco S. Trés
Gabriela Franco S. Trés
MSMirian Sotto
Mirian Sotto
Vasculitis is a group of several clinical conditions in which the main histopathological finding is fibrinoid necrosis in the walls of blood vessels. This article assesses the main dermatological aspects relevant to the clinical and laboratory diagnosis of small- and medium-vessel cutaneous and systemic vasculitis syndromes. The most important aspects of treatment are also discussed.

29 January 2020 in The International Journal of Lower Extremity Wounds
Verified
Journal Article
Closed access
PDF file
MPMarcella Soares Pincelli
Marcella Soares Pincelli
AEAlejandra Maria Jimenez Echavarria
Alejandra Maria Jimenez Echavarria
PCPaulo Criado
Paulo Criado
GMGabriela Franco Marques
Gabriela Franco Marques
TMThâmara Cristiane Alves Batista Morita
Thâmara Cristiane Alves Batista Morita
JCJosélio Freire de Carvalho
Josélio Freire de Carvalho
Livedo racemosa is a cutaneous finding characterized by a persistent, erythematous, or violaceous discoloration of the skin, in a broken, branched, discontinuous, and irregular pattern. A retrospective review of 33 cases with clinical diagnosis of livedo racemosa over the past 6 years was evaluated in the dermatology department of a tertiary care hospital. We found predominance in Caucasian women (78.8%); age ranged from 8 to 81 years, with a mean age of 36 years. Livedo racemosa was described as generalized in 12 patients (36.4%), although the main localization was on lower limbs (42%). After laboratory testing and histopathological examinations, 12 patients (36.4%) were classified with idiopathic livedo racemosa; secondary diseases were diagnosis in 21 patients (63.6%), including Sneddon’s syndrome, cutaneous polyarteritis nodosa, systemic lupus erythematosus, and others. Medical history of thrombotic events was described in 8 (24.2%) patients, and also 8 (24.2%) patients had abnormal results for 2 or more thrombophilia laboratory tests. Skin biopsy showed no histological abnormalities in 11 cases (33.3%), thrombosis of dermal blood vessels in 10 (30.3%), intimal/subintimal thickening in 7 (21.2%), and vasculitis in 5 (15.2%). In conclusion, livedo racemosa is a clinical feature that might be correlated to vascular disorders, such as thrombotic and/or hypercoagulable states, autoimmune diseases, and neoplastic diseases, or it can be secondary to specific medications. It is essential to establish a correct approach in cases of livedo racemosa, which includes anamnesis, physical examination, laboratory test, histological examination, and complementary examination according to clinical findings, in order to diagnosis underlying causes.

16 April 2018 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
GMGabriela Franco Marques
Gabriela Franco Marques
PCPaulo Criado
Paulo Criado
TMThâmara Cristiane Alves Batista Morita
Thâmara Cristiane Alves Batista Morita
MGMaría Salomé Cajas García
María Salomé Cajas García